IMMXImmix Biopharma, Inc.
What is the market doing?
Rangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Choppy, but holding above its 200-day average. Oversold (RSI 23). Price is +1% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How IMMX is trading
Immix Biopharma, Inc. is +271% over the past year while the S&P 500 is +18%: 252 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +0.82%
vs 200-day average · close to trend
- RSI (14)
- 23
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 36%
Below its 52-week high
Details›
- Last close2026-10-08
- $9.30
- 1 monthS&P 500 +1.6%
- −24%
- 1 yearS&P 500 +18%
- +271%
- vs 50-day average$11.69
- −20%
- 52-week high
- $14.59
- 52-week low
- $2.48
- Annualised volatility
- 88%
| Year | Return |
|---|---|
| 2026 (year to date) | +78% |
| 2025 | +138% |
| 2024 | −68% |
| 2023 | +202% |
| 2022 | −36% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | −3.5% |
| Feb | 5 | 1 of 5 | −5.7% |
| Mar | 5 | 1 of 5 | −6.5% |
| Apr | 5 | 2 of 5 | −2.5% |
| May | 5 | 3 of 5 | +9.2% |
| Jun | 5 | 3 of 5 | +10% |
| Jul | 5 | 2 of 5 | −2.6% |
| Aug | 5 | 2 of 5 | +5.4% |
| Sep | 5 | 1 of 5 | −3.8% |
| Oct | 5 | 3 of 5 | +12% |
| Nov | 4 | 4 of 4 | +26% |
| Dec | 4 | 4 of 4 | +38% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.